A prospective, randomised, double-blinded, placebo-controlled, single ascending dose study investigating the safety and local tolerability of STA363 compared to placebo in 15 patients with chronic discogenic low back pain

Trial Profile

A prospective, randomised, double-blinded, placebo-controlled, single ascending dose study investigating the safety and local tolerability of STA363 compared to placebo in 15 patients with chronic discogenic low back pain

Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Jun 2017

At a glance

  • Drugs Lactic acid (Primary)
  • Indications Back pain
  • Focus Adverse reactions; First in man
  • Sponsors Stayble Therapeutics
  • Most Recent Events

    • 22 Jun 2017 Status changed from not yet recruiting to recruiting.
    • 20 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top